Clinuvel Pharmaceuticals Ltd
ASX:CUV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AIA Group Ltd
HKEX:1299
|
HK |
|
P
|
Porton Pharma Solutions Ltd
SZSE:300363
|
CN |
Clinuvel Pharmaceuticals Ltd
Cash from Operating Activities
Clinuvel Pharmaceuticals Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash from Operating Activities
AU$40.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Operating Activities
-$59.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Operating Activities
$3.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
0%
|
CAGR 10-Years
10%
|
|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
Cash from Operating Activities
-AU$7.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-192%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Operating Activities
-AU$17.3m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Operating Activities
-AU$65.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-58%
|
|
Clinuvel Pharmaceuticals Ltd
Glance View
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
See Also
What is Clinuvel Pharmaceuticals Ltd's Cash from Operating Activities?
Cash from Operating Activities
40.5m
AUD
Based on the financial report for Dec 31, 2025, Clinuvel Pharmaceuticals Ltd's Cash from Operating Activities amounts to 40.5m AUD.
What is Clinuvel Pharmaceuticals Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
17%
Over the last year, the Cash from Operating Activities growth was 70%. The average annual Cash from Operating Activities growth rates for Clinuvel Pharmaceuticals Ltd have been -2% over the past three years , 17% over the past five years .
